Low-risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer patients
(2010) In International Journal of Cancer 126(12). p.2858-2862- Abstract
- To validate common low-risk variants predisposing for breast cancer (BC) in a large set of BRCA1/2 negative familial or genetically enriched cases from Germany, we genotyped 1,415 cases and 1,830 healthy women by MALDI-TOF in 105 candidate SNPs. Significantly higher ORs than previously reported for heterozygous unselected cases were found for the minor allele in FGFR2 (OR = 1.43, 95% Cl 1.30-1.59, p-value = 1.24 x 10(-12)) and for TNRC9 (OR = 1.33, 95% Cl 1.19-1.46, p-value = 1.54 x 10(-7)). Most intriguing, however, were the ORs for homozygous carriers from high-risk families for FGFR2 (OR = 2.05, 95% Cl 1.68-2.51, LSP1 (OR = 0.49, 95% Cl 0.28-0.86) and TNRC9 (OR = 1.62, 95% Cl 1.27-2.07). Moreover, the additional validation of 99... (More)
- To validate common low-risk variants predisposing for breast cancer (BC) in a large set of BRCA1/2 negative familial or genetically enriched cases from Germany, we genotyped 1,415 cases and 1,830 healthy women by MALDI-TOF in 105 candidate SNPs. Significantly higher ORs than previously reported for heterozygous unselected cases were found for the minor allele in FGFR2 (OR = 1.43, 95% Cl 1.30-1.59, p-value = 1.24 x 10(-12)) and for TNRC9 (OR = 1.33, 95% Cl 1.19-1.46, p-value = 1.54 x 10(-7)). Most intriguing, however, were the ORs for homozygous carriers from high-risk families for FGFR2 (OR = 2.05, 95% Cl 1.68-2.51, LSP1 (OR = 0.49, 95% Cl 0.28-0.86) and TNRC9 (OR = 1.62, 95% Cl 1.27-2.07). Moreover, the additional validation of 99 CGEMS-SNPs identified putative novel susceptibility alleles within the LSP1 gene (OR = 0.73, 95% Cl 0.61-0.87, p-value = 5.23 x 10(-4)). Finally, we provide evidence for the first time that a low-risk variant located at 6q22.33 (rs6569479) is associated with estrogen receptor negative BC in familial cases (OR = 1.33, 95% Cl 1.06-1.66; p-value = 0.012). Our data confirm the impact of the previously identified susceptibility loci and provide preliminary evidence for novel susceptibility loci in familial BC cases and correlate them to specific histopathological subtypes defined by estrogen receptor status. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1617852
- author
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- breast cancer risk, polymorphism, familial breast cancer, SNP, CGEMS
- in
- International Journal of Cancer
- volume
- 126
- issue
- 12
- pages
- 2858 - 2862
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000277551100010
- scopus:77951911594
- pmid:19856316
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.24986
- language
- English
- LU publication?
- yes
- id
- 0d1ee085-50ec-442d-8f96-a15c4026dc47 (old id 1617852)
- date added to LUP
- 2016-04-01 10:38:23
- date last changed
- 2022-03-12 07:43:02
@article{0d1ee085-50ec-442d-8f96-a15c4026dc47, abstract = {{To validate common low-risk variants predisposing for breast cancer (BC) in a large set of BRCA1/2 negative familial or genetically enriched cases from Germany, we genotyped 1,415 cases and 1,830 healthy women by MALDI-TOF in 105 candidate SNPs. Significantly higher ORs than previously reported for heterozygous unselected cases were found for the minor allele in FGFR2 (OR = 1.43, 95% Cl 1.30-1.59, p-value = 1.24 x 10(-12)) and for TNRC9 (OR = 1.33, 95% Cl 1.19-1.46, p-value = 1.54 x 10(-7)). Most intriguing, however, were the ORs for homozygous carriers from high-risk families for FGFR2 (OR = 2.05, 95% Cl 1.68-2.51, LSP1 (OR = 0.49, 95% Cl 0.28-0.86) and TNRC9 (OR = 1.62, 95% Cl 1.27-2.07). Moreover, the additional validation of 99 CGEMS-SNPs identified putative novel susceptibility alleles within the LSP1 gene (OR = 0.73, 95% Cl 0.61-0.87, p-value = 5.23 x 10(-4)). Finally, we provide evidence for the first time that a low-risk variant located at 6q22.33 (rs6569479) is associated with estrogen receptor negative BC in familial cases (OR = 1.33, 95% Cl 1.06-1.66; p-value = 0.012). Our data confirm the impact of the previously identified susceptibility loci and provide preliminary evidence for novel susceptibility loci in familial BC cases and correlate them to specific histopathological subtypes defined by estrogen receptor status.}}, author = {{Hemminki, Kari and Mueller-Myhsok, Bertram and Lichtner, Peter and Engel, Christoph and Chen, Bowang and Burwinkel, Barbara and Försti, Asta and Sutter, Christian and Wappenschmidt, Barbara and Hellebrand, Heide and Illig, Thomas and Arnold, Norbert and Niederacher, Dieter and Dworniczak, Bernd and Deissler, Helmut and Kast, Karin and Gadzicki, Dorothea and Meitinger, Thomas and Wichmann, H. -Erich and Kiechle, Marion and Bartram, Claus R. and Schmutzler, Rita K. and Meindl, Alfons}}, issn = {{0020-7136}}, keywords = {{breast cancer risk; polymorphism; familial breast cancer; SNP; CGEMS}}, language = {{eng}}, number = {{12}}, pages = {{2858--2862}}, publisher = {{John Wiley & Sons Inc.}}, series = {{International Journal of Cancer}}, title = {{Low-risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer patients}}, url = {{http://dx.doi.org/10.1002/ijc.24986}}, doi = {{10.1002/ijc.24986}}, volume = {{126}}, year = {{2010}}, }